Benitec Biopharma Ltd ADR (BNTC)

3.050 +0.100 (+3.39%)
Closed USD Disclaimer
2.940 -0.110 (-3.607%)

Benitec Biopharma Ltd ADR Company Profile

Equity Type
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Contact Information
Hayward,94545 United States
510 780 0819
Top Executives
Geoffrey McCaughan 0 2015 Member of Hepatology Clinical Advisory Board
Peter Damian Francis 65 2006 Independent Non-Executive Director
George Dickson 0 0000 Member of Scientific & Clinical Advisory Board
Harry Janssen 0 2015 Member of Hepatology Clinical Advisory Board
Keyur Patel 0 2015 Member of Hepatology Clinical Advisory Board
Megan Joan Boston 49 2016 Executive Director
J. Kevin Buchi 66 2013 Independent Non-Executive Director
Jerel A. Banks 47 2016 Executive Chairman & CEO
Edward F. Smith 51 2020 Independent Non-Executive Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.